From Anvita Health Wiki
Introduction
- Tradename: Primaclone, Mysoline.
Indications
-
Dosage
- start 100-125 mg PO QHS
- increase over 10 days to 250 mg TID/ QID
- day 1-3: 100-125 mg QHS
- day 4-6: 100-125 mg BID
- day 7-9: 100-125 mg TID
- day 10: maintenance dose
- Tabs: 50 & 250 mg
- Liquid: 250 mg/5 mL .
Pharmacokinetics
-
-
- approximately 40% of drug excreted unchanged into urine
- elimination 1/2life
-
Monitor
-
Adverse-effects
-
-
-
-
-
Drug-interactions
-
-
Laboratory
-
-
Mechanism-of-action
-
More General Terms
Additional Terms
- cytochrome p450 1A2 (cytochrome P3-450, phenacetin deethylase, cytochrome p450-4, CYP1A2)
- cytochrome P450 2C9; cytochrome P450 BP-1; cytochrome P450 MP-4; S-mephenytoin-4-hydroxylase; limonene 6-monooxygenase; limonene 7-monooxygenase (CYP2C9, CYP2C10)
- cytochrome P450 3A4 (cytochrome P450 C3, nifedipine oxidase, P450-PCN1, NF-25, CYP3A4)
- phenobarbital; PB; PHB (Luminal, Barbita, Solfoton)
- primidone in serum/plasma
Internet Database
PubChem: 4909
PubChem: 589869
References
- The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- Harrison's Principles of Internal Medicine, 13th ed. Companion Handbook. Isselbacher et al (eds), McGraw-Hill Inc. NY, 1995, pg 700.
- The Pharmacological Basis of Therapeutics, 8th ed. Gilman et al, eds. Permagon Press/McGraw Hill pg 446
- Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
- Kaiser Permanente Northern California Regional Drug Formulary, 1998
- Clinical Guide to Laboratory Tests, NW Tietz (ed) 3rd ed, WB Saunders, Philadelpha 1995
- Prescriber's Letter 13(3): 2006 Cytochrome P450 drug interactions Detail-Document#: [1] (subscription needed) [2]
- Anvita Health guideline :id 1686
primidone; desoxyphenobarbital (Primaclone, Mysoline)